Market Valuation & Earnings Multiples
Market capitalization, P/E ratios, and enterprise value
Market Cap2.15B
Enterprise Value1.94B
Trailing P/E96.20
SLNO
(NASDAQ)Soleno Therapeutics, Inc.
$39.49-- (--)
Loading... - Market loading
Soleno Therapeutics (SLNO) Key Statistics & Financial Metrics
Complete stock analysis with 40+ metrics: valuation ratios, profitability margins, financial health indicators, and dividend data.
Stock Valuation Metrics
Market value, earnings multiples, and pricing ratios
Price-Based Ratios
Valuation ratios based on stock price
Price/Sales (ttm)10.55
Price/Book (mrq)4.46
Price/Tangible Book (mrq)4.51
Price/FCF (ttm)43.01
Price/OCF (ttm)42.94
Enterprise Value Ratios
EV-based valuation multiples
EV/Revenue10.20
EV/Earnings92.98
EV/EBITDA68.43
EV/EBIT-28.43
EV/FCF41.57
Stock Price
Current price, 52-week range, and moving averages
Current Price$39.49
1-Day Change10.48%
52-Week High$90.32
52-Week Low$29.43
52-Week Change-45.81%
YTD Change-21.58%
1-Year Change-49.79%
50-Day MA$38.07
200-Day MA$57.50
Avg Volume (30 day)3.57M
Share Statistics
Outstanding shares, float, and per-share metrics
Shares Outstanding54.33M
Book Value per Share$8.28
Net Cash per Share$1.28
FCF per Share$0.86
Analyst Price Targets & Consensus
Wall Street analyst ratings and 12-month price targets (90 days)
Price Target$93.75
Target Upside/Downside137.40%
Analyst ConsensusBuy
Analyst Count4
Profitability & Financial Performance
Profit margins, return metrics, and earnings analysis
Profit Margins
Profitability margins across income statement
Gross Margin98.58%
EBITDA Margin (ttm)14.91%
EBIT Margin (ttm)-35.88%
Operating Margin (ttm)7.85%
Pretax Margin (ttm)10.97%
Profit Margin (ttm)10.97%
FCF Margin (ttm)24.54%
Return on Investment Metrics
ROE, ROA, ROIC, and capital efficiency ratios
Return on Equity (ttm)4.64%
Return on Assets (ttm)3.71%
Return on Invested Capital (ttm)-17.85%
Return on Capital Employed (ttm)-13.60%
Income Statement (TTM)
Trailing twelve months revenue and earnings
Revenue190.41M
Gross Profit187.71M
Operating Income14.95M
Pretax Income20.89M
Net Income20.89M
EBITDA28.38M
EBIT-68.32M
Diluted EPS$0.38
Cash Flow (TTM)
Operating cash flow and free cash flow metrics
Operating Cash Flow46.80M
Capital Expenditures73.00K
Free Cash Flow46.73M
Growth Rates (YoY)
Year-over-year growth metrics
Financial Health & Dividends
Balance sheet analysis, debt ratios, and dividend metrics
Assets & Cash
Total assets and cash positions
Total Assets (mrq)563.83M
Cash & Securities (mrq)70.11M
Net Cash (mrq)69.38M
Net Cash per Share$1.28
Debt & Liabilities
Liabilities, debt, equity, and working capital
Total Debt (mrq)2.69M
Working Capital (mrq)294.45M
Total Equity (mrq)450.12M
Book Value per Share$8.28
Liquidity & Leverage
Liquidity, leverage, and debt coverage ratios
Current Ratio (mrq)5.80
Quick Ratio (mrq)5.55
Debt/Equity (mrq)0.01
Debt/EBITDA (ttm)0.09
Debt/FCF (ttm)0.06
Dividend History & Payout Analysis
Dividend yield, payout ratios, and growth metrics
Dividend per Share (TTM)$0.00
Dividend Yield0.00%
Payout Ratio (Earnings)0.00%
Yield Metrics
Earnings, FCF, buyback, and shareholder yields
Earnings Yield1.04%
FCF Yield2.32%
Buyback Yield4.98%
Total Shareholder Yield4.98%
Financial Health Scores
Risk assessment and quality metrics
Altman Z-Score10.10
Piotroski F-Score6/9
Fair Value & Intrinsic Value
Lynch fair value, Graham number, and valuation models
Graham Number$8.47
Graham Upside/Downside-77.11%
Frequently Asked Questions About Soleno Therapeutics Statistics
What are the key financial metrics for SLNO?
Soleno Therapeutics, Inc. (SLNO) statistics include 40+ financial metrics organized into valuation ratios (P/E, P/S, P/B, PEG), profitability margins (gross, operating, net), return metrics (ROE, ROA, ROIC), and financial health indicators. These are updated regularly based on the latest filings and market data.
What is SLNO's valuation analysis?
The valuation section covers market capitalization, earnings multiples like trailing and forward P/E, price-based ratios (P/S, P/B, Price/FCF), and enterprise value ratios (EV/EBITDA, EV/Revenue, EV/FCF). Compare these against sector averages to assess whether Soleno Therapeutics is overvalued or undervalued.
How do I read SLNO's profitability ratios?
Soleno Therapeutics's profitability is measured through profit margins (gross, EBITDA, operating, net) and return metrics (ROE, ROA, ROIC, ROCE). Higher margins indicate better cost control, while higher returns show efficient capital deployment. The income statement and cash flow sections provide the underlying revenue and earnings data.
What do SLNO's debt ratios indicate?
The financial health section shows Soleno Therapeutics's leverage through debt-to-equity, debt-to-assets, debt-to-EBITDA, and debt-to-FCF ratios, plus liquidity via the current and quick ratios. Lower debt ratios and higher liquidity ratios generally indicate stronger financial stability and lower default risk.
What is SLNO's dividend analysis?
The dividend section covers Soleno Therapeutics's dividend yield, payout ratios (earnings-based and FCF-based), year-over-year dividend growth, years of consecutive growth, ex-dividend and pay dates, and payment frequency. The yield metrics section also includes earnings yield, FCF yield, buyback yield, and total shareholder yield.